AK

Ajit Kumar Tripathy

Active Director Designated Partner DIN 06924287
DIN 06924287 First appointment Oct 2014 Primary industry Research & Development
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Oct 2014
Shareholding value β€’β€’β€’β€’ Premium profile

About Ajit Kumar Tripathy

Data last updated:

Ajit Kumar Tripathy is a Designated Partner at Clinopsys Clinical Research Llp (since 2014). The company operates in Research & Development.

DIN 06924287
Primary Designation Designated Partner
Industry Research & Development
First Appointment 01 Oct 2014
Oldest Company Age 12 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Designated Partner01 Oct 20142014Active

Board colleagues of Ajit Kumar Tripathy

NameDINCompanyDesignation
Tuhin Subhra Chakraborthy06924292Clinopsys Clinical Research LlpDesignated Partner

Directorship timeline

Open interactive timeline →
Clinopsys Clinical Research Llp
Premium access

Shareholding and investment profile for Ajit Kumar Tripathy

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Ajit Kumar Tripathy

Ajit Kumar Tripathy currently holds 1 directorship: Clinopsys Clinical Research Llp (Designated Partner, since 01 Oct 2014).

Ajit Kumar Tripathy was first appointed on 01 Oct 2014 as Designated Partner at Clinopsys Clinical Research Llp.

The current boards of Ajit Kumar Tripathy's companies include Tuhin Subhra Chakraborthy (Clinopsys Clinical Research Llp).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available